Table 3.
Association between type of treatment and clinical variables
| Clinical variables | ICIs | CHTs | n | p-value* |
|---|---|---|---|---|
| SARS-CoV2 IgG/IgM | ||||
| IgG and/or IgM+ | 9 | 39 | 885 | 0.04 |
| IgG and IgM− | 278 | 559 | ||
| Gender | ||||
| Male | 154 | 207 | 885 | < 0.001 |
| Female | 133 | 391 | ||
| Age (years) | ||||
| < 70 | 194 | 416 | 885 | n.s |
| ≥ 70 | 93 | 182 | ||
| Cancer stage | ||||
| I–III | 38 | 97 | 804 | 0.05 |
| IV | 249 | 420 | ||
| ECOG performance status | ||||
| 0 | 244 | 265 | 793 | < 0.001 |
| 1–4 | 41 | 243 | ||
| Lymphopenia | ||||
| Yes | 2 | 90 | 755 | < 0.001 |
| No | 256 | 407 | ||
| Leukopenia | ||||
| Yes | 0 | 91 | 764 | < 0.001 |
| No | 258 | 415 | ||
ICIs Immune Checkpoint Inhibitors Treatment, CHTs chemotherapy treatments, n number of patients, n.s not statistically significant
*The p-values represent χ2 tests of independence indicating associations between type of treatment and categorical clinical variables (statistically significant p < 0.05)